AMBRX, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2003-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.ambrx.com
Clinical Trials
5
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:2
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (60.0%)Phase 1
2 (40.0%)ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
Phase 2
Withdrawn
- Conditions
- HER2 Mutation-Related TumorsHER2 Amplified Solid Tumors
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Ambrx, Inc.
- Registration Number
- NCT05041972
- Locations
- 🇺🇸
Mount Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸AMR Kansas City, Kansas City, Missouri, United States
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Ambrx, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT04829604
- Locations
- 🇰🇷
Research Site, Suwon, Korea, Republic of
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Ambrx, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT03255070
- Locations
- 🇺🇸
USC Norris Cancer Hospital, Los Angeles, California, United States
🇺🇸UCLA Hematology-Oncology, Santa Monica, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Safety, Tolerability and PK/PD Study in Young Adult Patients With Childhood Onset Growth Hormone Deficiency (GHD).
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2009-10-12
- Lead Sponsor
- Ambrx, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00778518
- Locations
- 🇭🇺
Accelsiors CRO and Consultancy Services, Budapest, Hungary
News
No news found